Chandra Mohan | Medicinal Chemistry | Excellence in Research

Posted on by Top Pharmaceutical

Chandra Mohan | Medicinal Chemistry | Excellence in Research

Assoc. Prof. Dr. Chandra Mohan at K R Mangalam University, Gurugram, India.

Assoc. Prof. Dr. Chandra Mohan is an accomplished researcher and educator in Inorganic Chemistry with a Ph.D. in chemical sensors 🧪. Currently serving at K.R. Mangalam University, he has over 12 years of academic experience 📚. His expertise spans green chemistry, nanomaterials, and environmental sustainability 🌱. With global collaborations 🌍, 12 authored/edited books 📘, and 15 book chapters, he is a driving force in sustainable science. Dr. Mohan has guided multiple Ph.D. scholars 🎓, led funded projects, and organized international conferences. His dynamic contributions continue to inspire innovation, education, and impactful research across borders.

Publication Profile 

Google Scholar

Education

Assoc. Prof. Dr. Chandra Mohan holds a Ph.D. in Inorganic Chemistry 🧪 from Guru Gobind Singh Indraprastha University, specializing in chemical sensors. He is currently a Post-Doctoral Scholar at Amity University, Dubai 🏙️. He also earned an MBA in HR + IT in 2024 📊. Dr. Mohan has completed an M.Phil. in acid catalysts from the University of Delhi 🧫 and an M.Sc. in Applied Chemistry from MDSU 🧬. His academic journey began with a B.Sc. in PCM 📘 and included a diploma in computer programming 💻. He also qualified GATE (Chemistry) in 2013 ✅, showcasing his scholarly depth.

Experience

Assoc. Prof. Dr. Chandra Mohan brings over 13 years of dedicated academic experience to the field of chemistry education 🧪. Since August 2023, he has served as an Associate Professor at K. R. Mangalam University, Gurugram 🏫. Prior to that, he held the position of Assistant Professor at the same university from 2013 to 2023, contributing a solid decade of teaching, research, and academic leadership 📚. His early academic journey began at HMRITM College, affiliated with GGSIPU, Delhi, where he served as Assistant Professor from January 2010 to February 2011 👨‍🔬, marking the foundation of his scholarly path.

Awards 

Assoc. Prof. Dr. Chandra Mohan has been widely recognized for his academic brilliance and social contributions 🎓🌍. He received the Advanced Materials Award from IAAM, Sweden 🇸🇪 in 2024 and the Best Researcher Award from ScienceFather in 2023 🔬. His passion for innovation earned him the Young Researcher Award by IARC, Kenya 🇰🇪 in 2022 and Best Paper Award at DAM2IC the same year 📄. With consecutive Legal Awareness Awards (2020–2022) and honors for Social Services and Youth Engagement 🇮🇳, he exemplifies academic excellence and civic responsibility. He also received the Young Faculty Award in 2016 & 2018.

Research Focus 

Assoc. Prof. Dr. Chandra Mohan specializes in Inorganic Chemistry, with a strong research focus on chemical sensors, coordination chemistry, nanocomposites, and sustainable environmental materials 🌱🧪. His expertise spans Schiff base metal complexes, clay mineral applications, and green chemistry approaches for drug design 💊 and water treatment 💧. He actively explores polymer composites, ion-selective electrodes, and biocompatible catalysts for eco-friendly industrial solutions 🌍. His interdisciplinary collaborations extend to bioplastics, AI in sustainability, and agricultural innovations 🌾, highlighting his dedication to solving real-world problems through chemistry and materials science.

Publication Top Notes

Premal Thaker | Clinical Trials | Best Researcher Award

Posted on by Top Pharmaceutical

Premal Thaker | Clinical Trials | Best Researcher Award

Dr. Premal Thaker at Washington University School of Medicine, United States.

Dr. Premal Thaker is a renowned gynecologic oncologist and professor at Washington University, St. Louis. With a medical degree from Allegheny University and advanced training at MD Anderson Cancer Center, she has led impactful clinical research in ovarian and endometrial cancers 🧪. As Director of Gynecologic Oncology Clinical Research and Division Chief (2025–present), her leadership is pivotal in advancing cancer therapies. A respected speaker, grant recipient, and editorial board member 📚, Dr. Thaker has earned numerous accolades including “Best Doctors in America” and “Castle Connolly Top Doctor” 🏅. Her dedication to women’s health continues to inspire globally.

Publication Profile 

Scopus

Education

Dr. Premal Thaker’s illustrious academic journey began with a BA in Biology from Villanova University 🎓, followed by an MD from Allegheny University and an MS in Cancer Biology from the University of Texas 🧬. She completed specialized training in gynecologic oncology at MD Anderson Cancer Center and recently attended a leadership course at Harvard 🏛️. Dr. Thaker has held esteemed positions at Washington University, advancing from Assistant Professor to Division Chief of Gynecologic Oncology 👩‍⚕️. A distinguished researcher and educator, she is also the David and Lynn Mutch Distinguished Professor and Director of Clinical Research.

Awards

Dr. Premal Thaker has received numerous accolades throughout her distinguished career in gynecologic oncology 🎖️. Beginning with academic honors such as the Dean’s List and Alpha Epsilon Delta Honor Society in the early 1990s 📚, she went on to earn prestigious awards for scientific presentations and publications, including the J.G. Moore Award 🧪 and GCF/Eli Lilly Fellow Award 🧬. Recognized as one of the Best Doctors in St. Louis (2013–2025) and America (2020–2024) 👩‍⚕️, she was also named a Castle Connolly Top Doctor and Fellow of AGOS. In 2025, she joined Avant-Garde Health’s Research All-Stars.

Research Focus 

Dr. Premal Thaker’s research primarily centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers 🧫. Her work explores immune checkpoint inhibitors, personalized gene therapy, molecular profiling, and health disparities in clinical trial enrollment, particularly in Hispanic and Asian populations 🌍. She also investigates novel immunotherapy combinations, real-world treatment outcomes, and genomic biomarkers for therapy response and survival 🧪. Her multidisciplinary efforts contribute to precision medicine and the advancement of targeted therapies for women’s reproductive cancers, driving impactful, patient-centered innovations in oncology care.

Publication Top Notes

  • Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
  • OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
  • Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
  • Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
  • Diverse case series of granulomatous peritonitis mimicking advanced ovarian cancer
  • Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
  • Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis
  • Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
  • Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma
  • Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study

Moses Owoicho Abah | Bioinformatics in Pharmaceuticals | Best Researcher Award

Posted on by Top Pharmaceutical

Moses Owoicho Abah | Bioinformatics in Pharmaceuticals | Best Researcher Award

Dr. Moses Owoicho Abah at World-Class Research Center “Digital biodesign and personalized healthcare”, Sechenov First Moscow State Medical University, Moscow, Russia, Russia.

Dr. Moses Owoicho Abah is a passionate cancer researcher and molecular oncologist 🧪, currently pursuing a Ph.D. in Oncology/Radiation Therapy 🎓 at I.M. Sechenov First Moscow Medical University. With academic roots in Biochemistry, Bioinformatics, and Medical Biochemistry 🧠, he specializes in RNA sequencing, immunoassays, and biomarker discovery. Dr. Abah has worked across leading institutions in Nigeria and Russia 🇳🇬🇷🇺, contributing to drug discovery, genomics, and personalized oncology. He brings deep expertise in data analysis using Python and R 📊, and his impactful research is published in Scopus-indexed journals 📚. His goal is to revolutionize cancer treatment globally.

Publication Profile 

Google Scholar

Education

Dr. Moses Owoicho Abah’s educational path reflects his unwavering dedication to biomedical sciences and cancer research 🧬. He is currently pursuing a Ph.D. in Oncology/Radiation Therapy (2022–2025) at the Institute for Personalized Oncology, I.M. Sechenov First Moscow Medical University 🇷🇺. He earned his M.Sc in Medical Biochemistry (2020–2022) from the University of Abuja 🇳🇬 and completed a Professional Program in Bioinformatics (2019–2020) at MIPT, Russia. His foundation lies in a B.Sc (Hons) in Biochemistry (2010–2015) from FUAM and a Senior School Certificate from GSS Otukpo (2002–2007) 📚. His journey blends science, research, and innovation.

Experience

Since February 2025, Dr. Moses Owoicho Abah has served as a Cancer Research Coordinator at the Genetics, Genomics, and Bioinformatics Department of the National Institute for Cancer Research and Treatment, Nigeria 🇳🇬. He collaborates closely with the Principal Investigator to uphold global research standards 🌍, prepares proposals, budgets, protocols 📄, and handles informed consent and participant screening ✅. Skilled in RStudio and Python 📊🐍, he generates complex data visuals, manages study supplies, and maintains communication with stakeholders. He also revises and submits manuscripts to top journals 📚, contributing meaningfully to global cancer research.

Awards

Dr. Moses Owoicho Abah has received multiple prestigious awards for his excellence in research and academics 🎓. In July 2021, he was honored with the Associate Fellow Award (CMRf-Bioinformatics) by the Royal Society of Clinical and Academic Researchers of Nigeria (ROSCARON) 🧬. In February 2020, he emerged Overall Best Scholar in Clinical Medicine, Chemistry & Biology during the Russian Open Door Scholarship competition 🇷🇺. Earlier, in August 2018, he was conferred an Honorary Fellow Award by the Association of Economists and Statisticians of Nigeria (AESN) 📈—a testament to his cross-disciplinary brilliance.

Research Focus 

Dr. Moses Owoicho Abah’s research lies at the intersection of oncology, molecular medicine, and bioinformatics 🧪. His work focuses on cancer biology, particularly angiogenesis, cytokine signaling, and drug resistance mechanisms in lung and renal cancers 💉🩸. He explores innovative therapies targeting biomarkers using comparative transcriptomics and RNA sequencing for precision medicine. Additionally, he investigates the toxicological effects of everyday compounds, such as triclosan 🧼, and their impact on hormonal balance. His studies also include natural product pharmacology and the anti-diabetic potential of medicinal plants 🌿, bridging traditional medicine with modern therapeutic strategies.

Publication Top Notes

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Posted on by Top Pharmaceutical

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Prof. Khaydar Yunusov at Institute of Polymer Chemistry and Physics Uzbekistan Academy of Sciences, Uzbekistan.

Prof. Khaydar Yunusov is a distinguished polymer chemist from Uzbekistan with extensive expertise in nanotechnology, cellulose chemistry, and biomaterials. Since 2007, he has held key research and leadership roles at the Institute of Polymer Chemistry and Physics, contributing significantly to polymer-based biomedical innovations. 💊 He holds a Doctor of Science and leads groundbreaking projects on nanostructured antibacterial films, antiviral eye medications, and burn treatments. 📘 With several patents, international collaborations 🌍, and editorial roles in leading journals, Prof. Yunusov is a pioneering force in sustainable polymer research and nanomedical applications.

Publication Profile 

Orcid

Education

Prof. Khaydar Yunusov began his academic journey at the Tashkent Chemical Technological Institute, earning a Bachelor’s degree in Chemistry (2006) and a Master’s in Cellulose, Paper Chemistry, and Technology (2008). 📘 Driven by scientific excellence, he pursued a Doctor of Science in Technical Sciences (2009–2016), focusing on advanced polymer research. Since 2018, he has served as a Senior Scientific Researcher in Nanochemistry, Nanophysics, and Nanotechnology. 🧪 His research delves into nanostructured bactericidal preparations based on cellulose and its derivatives, emphasizing synthesis, properties, and production technologies. 🧬 His academic background provides a solid foundation for pioneering innovations in polymer science.

Experience

Prof. Khaydar Yunusov has cultivated a rich professional career in polymer science, beginning in 2007 as a researcher at the Institute of Polymer Chemistry and Physics, Uzbek Academy of Sciences, Tashkent. 📍 Over the years, he advanced through roles including junior researcher, senior researcher, and project manager, earning his Doctor of Science along the way. 🔬 His expertise spans polymer and cellulose chemistry, nanotechnology, and biomaterials. From 2019 to 2023, he served as a lab and project manager, driving innovation in nanostructured materials. 💼 Prof. Yunusov’s professional path reflects unwavering dedication to scientific discovery and technological advancement.

Research Focus 

Prof. Khaydar Yunusov is a pioneering scientist whose research spans polymer chemistry, cellulose technology, and nanochemistry. His core focus lies in designing biocompatible nanomaterials 🧫 such as nanostructured drug delivery systems, microneedles, hydrogels, and functional films for medical applications 🎯. He actively explores biodegradable polymers, nanoparticle synthesis (silver, selenium, zinc oxide), and antimicrobial and anticancer therapies 💊. His work intersects biotechnology, materials science, and pharmaceutical engineering, advancing targeted treatments and regenerative medicine 🧠🦠. With numerous high-impact publications, Prof. Yunusov is shaping the future of smart biomaterials and sustainable polymeric solutions.

Publication Top Notes

  • A red cell membrane-camouflaged nanoreactor for enhanced starvation/chemodynamic/ion interference therapy for breast cancer
  • A three-dimensional printable conductive composite dressing for accelerating wound healing under electrical stimulation
  • Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management ( vol 12, pg 1064, 2024)
  • Fabrication of hollow microneedles with double-layer shell structure for rapid and prolonged local anesthesia
  • Homemade isothermal amplification-initiated Cas14a assay for rapid quantitative detection of aquatic RNA virus gene with no PAM
  • Iontophoresis-driven transdermal drug delivery system based on porous microneedles for hyperuricemia treatment
  • Real-time microbial growth curve (RMGC) system: an improved microplate reader with a graphical interface for automatic and high-throughput monitoring of microbial growth curves
  • Two-directions mechanical strength and high-barrier mechanisms of cellulose nanocrystal- based hybrids reinforced packaging with nacre-mimetic structure
  • Physico-chemical characteristics of dialdehyde carboxymethylcellulose/sericin graft copolymer
  • Synthesis, Characterization, and Cytotoxic Activity of Stable Selenium Nanoparticles‐Incorporated Carboxymethylcellulose Solution
  • Impact of cellulose supramolecular structure on its carboxymethylation reaction activity
  • Advances in the formation and properties of nanofiber biomaterials from polyvinyl alcohol/carboxymethylcellulose/nanosilver systems for medical applications
  • Obtaining Dialdehyde Carboxymethylcellulose Through Microwave Treatment
  • Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management

Borros Arneth | Pharmacology | Best Researcher Award

Posted on by Top Pharmaceutical

Borros Arneth | Pharmacology | Best Researcher Award

Dr. Borros Arneth at Justus Liebig University Giessen and Philipps University Marburg Germany, Germany.

Dr. Borros Michael Arneth (born August 5, 1973) is a distinguished German physician and laboratory medicine expert 🧪. He studied medicine, chemistry, and biochemistry at Goethe University Frankfurt and earned his Dr. med. with research on HIV via MR spectroscopy 🧠. With board certification in Laboratory Medicine and EurClinChem recognition, he has held leading roles at TU Dresden and Giessen-Marburg University Hospital 🏥. His expertise spans neonatal screening, hematology, and molecular diagnostics 🧫. Dr. Arneth is also an editor and reviewer for top journals 📚 and a recipient of prestigious scholarships like Studienstiftung des Deutschen Volkes.

Publication Profile 

Google Scholar

Education

Dr. Borros Arneth, born on August 5, 1973, in Bad Homburg, has cultivated a remarkable academic and professional career in medicine 🧬 and chemistry ⚗️. He pursued dual studies at Johann Wolfgang Goethe University, earning his Dr. med. with a focus on HIV diagnostics via MR spectroscopy 🧠. Recognized as a European Specialist in Clinical Chemistry and Laboratory Medicine (EurClinChem) 🇪🇺, he advanced through intensive training in Frankfurt, Mainz, and Dresden. His professional scope includes neonatal screening 👶🧪, hematology 🩸, and molecular diagnostics 🔬, making him a leading voice in laboratory medicine and biomedical innovation.

Teaching Contributions

Dr. Borros Arneth has made impactful teaching contributions at Universitätsklinikum Giessen Marburg, where he serves as head of key sections 🧬🩸, including hematology, neonatal screening 👶, and molecular diagnostics 🔬. As a dedicated university lecturer (Lehrbeauftragter) 👨‍🏫, Dr. Arneth plays a vital role in shaping the future of clinical laboratory medicine. His passion for academic mentorship 🌟 and knowledge transfer has guided numerous medical students and young professionals toward excellence. Through his integrated teaching and clinical responsibilities, he continues to inspire innovation, ethical practice, and critical thinking in the next generation of laboratory physicians.

Research Focus 

Dr. Borros Arneth’s research expertise spans clinical biochemistry, immunology, and neurological disorders, with a strong emphasis on the tumor microenvironment 🧫, multiple sclerosis 🧠, and biomarker discovery in autoimmune and psychiatric diseases 🧬. His notable work includes investigations into liquid biopsies 💉, CYP2D6 pharmacogenomics 💊, and gut-brain axis communication 🌱➡️🧠. Additionally, he explores trained innate immunity 🛡️, diabetes metabolomics 🍭, and light chain analysis in CSF for CNS diseases. Through interdisciplinary integration, Dr. Arneth advances precision diagnostics and translational medicine for complex chronic and neurological conditions.

Publication Top Notes

chenguang zhang | Endocrine Pharmacology | Best Researcher Award

Posted on by Top Pharmaceutical

chenguang zhang | Endocrine Pharmacology | Best Researcher Award

Dr. chenguang zhang at The Tumor Hospital of Xinjiang Medical University, China.

Dr. Chenguang Zhang 🧑‍⚕️ is a distinguished breast cancer surgeon and researcher, renowned for his expertise in diagnosing and treating both benign and malignant breast tumors. 🩺 He excels in surgeries including mastectomy, breast-conserving techniques, and reconstruction. 🧬 His cutting-edge research focuses on endocrine therapy resistance and molecular mechanisms in breast cancer, leading multiple high-level funded projects. 🔬 He holds a patent for surgical forceps 🛠️ and has authored numerous publications in SCI-indexed journals 📚. As a committed academic and member of several prestigious medical associations 🤝, Dr. Zhang is driving innovation in cancer diagnosis, treatment, and personalized care.

Publication Profile 

Orcid

Education

Dr. Chenguang Zhang 🧑‍⚕️ is highly proficient in the differential diagnosis of benign and malignant breast tumors 🔬. He is skilled in advanced breast cancer surgical techniques, including modified radical mastectomy, breast-conserving surgery, sentinel lymph node biopsy, and both implant-based and autologous tissue breast reconstruction 🏥. His research primarily targets the mechanisms behind endocrine therapy resistance in breast cancer 🎯. A leader in scientific innovation, he has directed multiple high-impact research projects at provincial and ministerial levels 🧪📊. Dr. Zhang’s commitment to precision medicine and surgical excellence is shaping the future of breast oncology care.

Professional Memberships

Dr. Chenguang Zhang 🧑‍⚕️ is an active contributor to the advancement of breast oncology through multiple prestigious professional memberships 🤝. He is a member of the Young Scholars Group of Breast Oncology under the Oncology Branch of the Chinese Medical Association 🧬, and serves on the Professional Committee of Oncoplastic Surgery within the China Anti-Cancer Association 🎗️. He is part of the Youth Expert Group 🌟 and the Young Scholars Group of the Science Popularization Branch of the Chinese Medical Doctor Association 📚. Additionally, he contributes to the Breast Minimally Invasive Plastic Surgery and Reconstruction Group within the Rehabilitation Society of the China Anti-Cancer Association.

Research Focus 

Dr. Chenguang Zhang’s research 🧪 focuses on breast cancer biology 🩺, particularly triple-negative breast cancer (TNBC) and endocrine therapy resistance in ER-positive tumors. His studies explore molecular pathways such as PI3K/AKT/mTOR, Wnt signaling, ferroptosis regulation, and autophagy inhibition 🧬. He investigates prognostic biomarkers, drug resistance mechanisms 💊, and advanced surgical strategies including sentinel lymph node biopsy and reconstructive techniques 🔬. His work contributes significantly to precision oncology, translational medicine, and clinical innovation in breast tumor management 🎗️. With a strong emphasis on molecular diagnostics, therapeutic resistance, and immunological responses, his research advances breast cancer treatment outcomes globally.

Publication Top Notes

  • Typical presentation of neurofibromatosis type I in a patient with giant cutaneous neoplasm and café au lait spots: A case report.
  • FOXO4 suppresses cisplatin resistance of triple-negative breast cancer by inhibiting autophagy.
  • Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma.
  • A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
  • MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study.
  • HOXD Antisense Growth-Associated Long Noncoding RNA Promotes Triple-Negative Breast Cancer Progression by Activating Wnt Signaling Pathway.
  • Clinical study of combined application of indocyanine green and methylene blue for sentinel lymph node biopsy in breast cancer.
  • Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer.
  • Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.

ETTIE Rosenberg | Pharmaceutical Law and Ethics | Best Researcher Award

Posted on by Top Pharmaceutical

ETTIE Rosenberg | Pharmaceutical Law and Ethics | Best Researcher Award

Dr. ETTIE Rosenberg at West Coast University School of Pharmacy, United States.

Dr. Ettie Rosenberg, PharmD, JD 🎓⚖️ is a distinguished professor, pharmacist, and attorney with an impressive dual doctorate in Pharmacy and Law from USC and Southwestern Law School. With decades of experience, she blends expertise in pharmacy education, healthcare law, and ethics. 💊📚 She has held various leadership and teaching roles at West Coast University and contributed to community health through projects like Vote and Vax® 💉🗳️. A Supreme Court Bar member and expert forensic consultant, Dr. Rosenberg continues to inspire through innovation in teaching and interprofessional scholarship. 🌟👩‍🏫 Her work empowers future healthcare leaders and strengthens ethical practice in pharmacy.

Publication Profile 

Scopus

Education

Dr. Ettie Rosenberg 🎓 holds an exceptional academic background that spans both law and pharmacy. She earned her Juris Doctorate (JD) in 1999 from Southwestern University School of Law ⚖️ in Los Angeles, California, specializing in health law. Prior to that, she completed her Doctor of Pharmacy (PharmD) 💊 from the University of Southern California (USC). Her academic journey began with pre-pharmacy studies 🧪 at the University of California, Los Angeles (UCLA). Additionally, she is multilingual, fluent in Spanish, French, and Hebrew 🌍🗣️. This unique blend of legal and pharmaceutical expertise empowers her to lead across healthcare and education sectors.

Experience

Dr. Ettie Rosenberg, PharmD, JD 🎓 is a distinguished educator with a rich portfolio of academic contributions in pharmacy law, ethics, healthcare systems, and public health. She has consistently led and developed key courses such as PHAR 838 Pharmacy Law & Ethics ⚖️, PHAR 619 U.S. Healthcare Systems 🏥, and PHAR 623 Advocacy & Debate: Mock Trial 🎤. Her dynamic instruction spans across interprofessional ethics, substance abuse, evidence-based practice, and capstone courses. Through innovative teaching methods and real-world applications 💡📘, she empowers pharmacy students to navigate complex legal, ethical, and clinical challenges with competence and integrity.

Awards

Dr. Ettie Rosenberg, PharmD, JD 🌟 has earned numerous accolades throughout her illustrious career. She received the 2017 AACP Innovations in Teaching Honorable Mention 🏆 for her impactful mock trial teaching method and was honored as Professor of the Year (2016) 👩‍🏫 by West Coast University. Earlier recognitions include the 1998 Health Care Law Scholarship 💼, Harvard Bluebook Award for Editing 📘, and the 1991 Alumna of the Year Award 🎓. A member of the Rho Chi Pharmacy Honor Society since 1978 🧪, she also completed a pediatric oncology fellowship at USC that same year 🧒💊, showcasing her dedication to excellence in education and healthcare.

Research Focus 

Dr. Ettie Rosenberg’s research focus lies at the dynamic intersection of pharmacy law, ethics, and education ⚖️📚💊. As a legal and pharmacy scholar, she explores how legal frameworks impact pharmaceutical practices, patient rights, public health, and healthcare policy 🏥📜. Her academic endeavors emphasize mock trial simulations, inter-professional education, and evidence-based legal instruction within pharmacy curricula 🎓⚖️🔬. Dr. Rosenberg also investigates regulatory challenges, professional accountability, and law’s role in optimizing patient outcomes 🤝👩‍⚕️. Her interdisciplinary work fosters ethical decision-making and critical thinking among future pharmacists, bridging gaps between law, education, and clinical practice.

Publication Top Notes

  • UPJE: Most pharmacy law educators have heard of it, but support remains divided

Souhire Belloumi | Formulation Science | Best Researcher Award

Posted on by Top Pharmaceutical

Souhire Belloumi | Formulation Science | Best Researcher Award

Ms. Souhire Belloumi at Faculty of Sciences of Tunis and Center of Biotechnology of Borj Cedria, Tunisia.

Ms. Souhire Belloumi is a dynamic young researcher pursuing her Ph.D. in Biological Sciences at the University of Tunis El-Manar, Tunisia 🇹🇳. With dual Master’s degrees in Biological Sciences and Environmental Biomonitoring, and a Bachelor’s in Medical Biotechnology 🧫, she specializes in bioactive compounds, molecular diagnostics, and food preservation 🌿🍗. Her research spans from natural preservatives to vaccine development, combining LC-MS/MS, PCR, and biochemistry tools 🔍🧪. She has collaborated internationally, including a stint at the University of Pisa 🇮🇹, and authored multiple impactful publications 📚. Her passion lies in innovating sustainable solutions for health and food security.

Publication Profile 

Scopus

Education

Ms. Souhire Belloumi has cultivated a strong academic foundation in life sciences. She is currently pursuing her Ph.D. in Biological Sciences (2019–2024) at the University of Tunis El-Manar 🧬. Prior to this, she earned a Master’s in Biological Sciences (2018–2019) and another in Environmental Biomonitoring (2016–2018) from the University of Carthage 🌿🧪. Her academic journey began with a Bachelor’s degree in Medical Biotechnology with a focus on Molecular Engineering (2013–2016) at the High Institute of Medical Technologies, Tunis 🧫. Her multidisciplinary education equips her with robust expertise in molecular biology, environmental science, and biotechnology.

Experience

Ms. Souhire Belloumi has rich research experience across molecular biology, virology, and natural product chemistry. At the University of Pisa, Italy 🇮🇹 (Oct–Dec 2023), she characterized bioactive plant compounds using LC-MS/MS. As a Research Scientist at the Center of Biotechnology of Borj-Cedria (2020–2023), she explored natural biopreservatives 🧪 for poultry, partnering with Poulina Holdings 🐔. Earlier roles include research on essential oils, virus diagnostics 🌿🦠, and vaccine development at Tunisia’s Pasteur Institute 💉. Her hands-on work in molecular diagnostics, compound isolation, and industrial applications highlights her commitment to bridging lab research and real-world impact.

Research Focus 

Ms. Souhire Belloumi focuses her research on natural bioactive compounds with applications in food preservation, microbiology, and environmental health 🌿🍗🦠. Her work emphasizes the synergistic use of essential oils to extend the shelf life of poultry products, showcasing innovations in natural biopreservatives 🍃🧪. She skillfully integrates chemical analysis, molecular biology, and biochemistry to evaluate antimicrobial, antioxidant, and insecticidal properties of plant-derived substances 🔍💧🧬. Her interdisciplinary approach not only advances food safety and sustainability 🌍 but also contributes to the development of eco-friendly alternatives to synthetic preservatives 🚫🧫✅, making her a valuable asset in biotechnology and food science.

Publication Top Notes

  • Combined essential oils as natural chicken meat preservatives: chemical composition, biological activities, synergy and shelf-life extension potential

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Posted on by Top Pharmaceutical

Saikat Chaudhuri | Drug Discovery and Development | Best Researcher Award

Assist. Prof. Dr. Saikat Chaudhuri at CSIR-Central Leather Research Institute, India.

Assist. Prof. Dr. Saikat Chaudhuri is an accomplished organic chemist specializing in natural product synthesis and green chemistry. 🎓 He earned his Ph.D. from IISER Bhopal, focusing on Clavine alkaloids, and holds degrees from Visva Bharati and Burdwan Universities. 🏅 He is a recipient of the Young Scientist Award (2024) and prestigious UGC fellowships. At CSIR-CLRI, he teaches and mentors students across disciplines, guiding numerous projects and theses. 📚 His innovative research, backed by major grants, has led to impactful publications in synthesis and catalysis. 🧪 His work fuels advancements in affordable pharmaceutical chemistry and sustainable methodologies.

Publication Profile 

Orcid

Education

Assist. Prof. Dr. Saikat Chaudhuri holds an impressive academic background in organic chemistry. He completed his Ph.D. in Organic Chemistry from IISER Bhopal (2013–2017) under the mentorship of Prof. Alakesh Bisai, focusing on the total syntheses of naturally occurring Clavine alkaloids 🧪. Prior to this, he earned his M.Sc. in Organic Chemistry from Visva Bharati University (2010–2012) 📘 and a B.Sc. (Hons.) in Chemistry from Burdwan University (2007–2010) 🔬. His strong academic foundation laid the groundwork for his research excellence and innovative contributions to synthetic organic chemistry and drug development.

Awards

Assist. Prof. Dr. Saikat Chaudhuri has been recognized with several prestigious honors throughout his academic journey. In 2024, he received the Young Scientist Award from the CRS Society, Vidyasagar University 🌟. Earlier, he was awarded the esteemed Dr. D.S. Kothari Postdoctoral Fellowship (2019–2021) by UGC, Government of India 🧪. During his doctoral research, he was a recipient of both Junior Research Fellowship (JRF) and Senior Research Fellowship (SRF) from UGC-NET (2013–2017) 📚. His early promise was evident when he earned the Swami Vivekananda Merit-cum-Means Scholarship (2011–2012) from the Govt. of West Bengal.

Research Focus 

Assist. Prof. Dr. Saikat Chaudhuri is a rising expert in synthetic organic chemistry and medicinal chemistry. His research focuses on the development of novel synthetic methodologies 🧪 for constructing complex heterocycles, such as indoles, benzazepinoindoles, and spiro compounds 🌱. These molecules show promising biological activity, including antibacterial and antifungal properties 💊🦠. He also explores green chemistry approaches, metal-free catalysis, and the total synthesis of natural products 🌍. His work significantly contributes to drug discovery and design, making him a valuable contributor to pharmaceutical research and sustainable chemistry.

Publication Top Notes

  • Synthesis of Dihydro‐benzazepinoindoles via an Oxidative Pictet–Spengler Reaction
  • A New Homogeneous Catalyst for the Synthesis of 3,3′‐Bis(indolyl)methanes: Collective Synthesis of Arundine, Turbomycin B, Arsindoline A, and Tris(1H‐Indol‐3‐yl)methane*
  • A Transition Metal‐Free Strategy for Dihydrobenzazepinoindole via KI‐Mediated Oxidative Pictet–Spengler Reaction
  • Pentafluorophenol‐Catalyzed Metal‐Free Fischer Indole Synthesis: A Novel Approach to Carbazole Derivatives and Desbromoarborescidine A*
  • Water Mediated Chemoselective Synthesis of Novel Spiro Benzoxazinoindoline and Extended Synthesis of Spiro Benzoxazinoindene Derivatives*
  • A Practical and Metal‐Free Approach Towards Synthesis of Spiro‐Benzazepinoindole Derivatives via Pentafluorophenol Catalyzed Pictet‐Spengler Reaction**
  • Efficient, One‐Pot, Green Syntheses of Analogues of 3,4‐Dihydro‐2H Pyrroles as Potential New Antifungal and Antibacterial Agents.
  • A convenient proline catalysed Paal–Knorr synthesis of highly substituted pyrrole: construction of a pyrrolo[2,1-a]isoquinoline scaffold
  • Syntheses of Novel Spirobenzazepinoindole Derivatives via Lewis‐Acid Catalyzed Pictet‐Spengler Cyclization
  • Self-Healable Hydrogels from Vegetable Oil: Preparation, Mechanism, and Applications
  • A Comprehensive Review of Synthetic Approaches Toward Lamellarin D and its Analogous
  • Catalytic Asymmetric Approach to the Naturally Occurring Clavine Alkaloid, (+)-Lysergine
  • Harnessing leather waste in polymer matrix for sustainable smart <scp>shape‐stable</scp> phase change materials
  • Green synthetic approaches for medium ring-sized heterocycles of biological and pharmaceutical interest

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Posted on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis